Conclusions
In summary, our study demonstrated that stem cell collection is feasible after prolonged induction with isatuximab-RVd and did not lead to collection failure in this academic single centre cohort. Moreover, induction therapy with RVd (21-days) for four or six cycles did not negatively impact overall collection results.